Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

Summary

A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.

Conditions

• Mood Disorders
• Anxiety Disorders
• Psychotic Disorders

Interventions

OTHER

Personalised medication advice based on pharmacogenetic testing

Pharmacogenetic genotyping provides personalised medication advice on dosage and choice of currently available and legally approved medication based on the patient's pharmacogenetic profile

Sponsors & Collaborators

• Parnassia Psychiatric Institute

  collaborator UNKNOWN

• University of Belgrade

  collaborator OTHER

• University of Bonn

  collaborator OTHER

• Babes-Bolyai University

  collaborator OTHER

• State University of New York - Upstate Medical University

  collaborator OTHER

• Ludwig-Maximilians - University of Munich

  collaborator OTHER

• King's College London

  collaborator OTHER

• University of Barcelona

  collaborator OTHER

• Maastricht University Medical Center

  lead OTHER

Principal Investigators

• Roos van Westrhenen, Ass. Prof. · Parnassia Psychiatric Institute (Amsterdam)

• Roos van Westrhenen, Ass. Prof. · Parnassia Psychiatric Institute (Amsterdam)

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

16 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-02-23

Primary Completion

2026-09-30

Completion

2026-09-30

Countries

• United States
• Germany
• Netherlands
• Romania
• Serbia
• Spain
• United Kingdom

Study Locations